Studies on the inhibition of AmpC and other β-lactamases by cyclic boronates
Authors:
Open Access
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1863 (4) , 742-748
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (MR/N002679/1)
- Wellcome Trust
This publication has 34 references indexed in Scilit:
- Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant EnterobacteriaceaePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for EuropeThe Lancet Infectious Diseases, 2014
- Kinetics of Avibactam Inhibition against Class A, C, and D β-LactamasesJournal of Biological Chemistry, 2013
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Sulbactam/Ampicillin, a New Beta-Lactamase Inhibitor/Beta-Lactam Antibiotic CombinationDrug Intelligence & Clinical Pharmacy, 1988
- Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamasesAntimicrobial Agents and Chemotherapy, 1986
- The inhibition of class C β-lactamases by boronic acidsBiochemical Journal, 1983
- Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to β-lactamase producing bacteriaJournal of Antimicrobial Chemotherapy, 1981
- Reversible inhibitors of penicillinasesBiochemical Journal, 1978
- Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerusAntimicrobial Agents and Chemotherapy, 1977